Abstract
The first two patients to be treated with miltefosine for post-kala-azar dermal leishmaniasis (PKDL) are reported. One was a 26-year-old Ethiopian man who had been treated with sodium stibogluconate, for relapsing visceral leishmaniasis (VL), four times between August 2002 and March 2004. In January 2004 this patient was found to be seropositive for HIV and began antiretroviral treatment with stavudine, lamivudine and nevirapine. Five months later he developed clinical PKDL, with extensive cutaneous, conjunctival and oral mucosal involvement. The second patient was a 42-year-old Ethiopian man who was treated for relapsing VL in November 2003. He too was subsequently found to be seropositive for HIV and was treated with stavudine, lamivudine and nevirapine from May 2004. He developed a nodular rash of PKDL over his face and upper body 2 weeks after starting the antiretroviral therapy. Treatment of both patients with oral miltefosine, at 100 mg/day for 28 days, led to the complete regression of their PKDL lesions. When checked 3-6 months after the end of the miltesofine treatment, neither patient showed any signs of VL, PKDL or other HIV-associated disease.
Citations
Oct 4, 2011·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·D Huis in 't VeldR Colebunders
Jul 22, 2008·Transactions of the Royal Society of Tropical Medicine and Hygiene·Nasim Akhtar AnsariPoonam Salotra
Jul 27, 2012·The Journal of Antimicrobial Chemotherapy·Thomas P C DorloPeter J de Vries
Apr 11, 2008·Clinical Microbiology Reviews·Jorge AlvarJavier Moreno
Jul 4, 2013·Parasites & Vectors·Philippe DesjeuxEd E Zijlstra
Feb 9, 2012·The Indian Journal of Medical Research·Veeranoot Nissapatorn, Nongyao Sawangjaroen
Jul 9, 2009·Annals of Tropical Medicine and Parasitology·P ColliniJ Greig
May 22, 2013·Journal of Tropical Medicine·A M MusaA M El-Hassan
Aug 30, 2008·Expert Opinion on Drug Metabolism & Toxicology·Jonathan Josh Berman
Nov 26, 2010·Dermatologic Clinics·Erin Huiras Amerson, Toby A Maurer
Sep 15, 2007·The British Journal of Dermatology·S AntinoriL Meroni
Mar 25, 2010·The British Journal of Dermatology·T GelanewG Schönian
Jul 10, 2013·International Journal of Dermatology·Uzma FarooqPaolo Romanelli
Jun 11, 2010·International Journal of Dermatology·Sujay KhandpurVinod K Sharma
Sep 12, 2014·International Journal of Dermatology·V RameshPoonam Salotra
Feb 19, 2010·Expert Opinion on Pharmacotherapy·Mahreen Ameen
Nov 21, 2014·PLoS Neglected Tropical Diseases·Eduard E Zijlstra
May 18, 2016·BMJ Open·D MondalS Hamano
Sep 3, 2011·Current Opinion in Infectious Diseases·Dinesh Mondal, Md Gulam Musawwir Khan
Dec 13, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Naomi AronsonAlan Magill